Literaturangaben

Zeitschrift für Infektionstherapie 4.2023

Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie

Tularämie – Zu Lande, zu Wasser und in der Luft: Eine vielseitige Zoonose (Seite 38)

1.    Passiouk N, Heininger U. Ulceroglandular tularemia following contact with a boar. Pediatr Infect Dis J 2016; 35:453-555. PMID: 26658527.

2.    Whitten T, Bjork J, Neitzel D, Smith K, Sullivan M, Scheftel J. Notes from the field: Francisella tularensis type B infection from a fish hook injury - Minnesota, 2016. MMWR Morb Mortal Wkly Rep 2017; 66:194. PMID: 28231234. PMCID: PMC5657846.

3.    Ehrensperger F, Riederer L, Friedl A. Tularämie nach Angriff eines Mäusebussards auf eine Joggerin: Ein „One Health“-Fallbericht. SAT 2018; 160:185-188.

4.    McCoy GW. A plague-like disease of rodents. Public Health Bull 1911; 43:  53-71.

5.    McCoy GW, Chapin CW. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent, bacterium tularense. Journal of Infectious Diseases 1912; 10:61-72.

6.    McCoy GW, Chapin CW. Bacterium tularense, the cause of a plaguelike disease of rodents. Public Health Bull 1912; 53:17-23.

7.    https://emergency.cdc.gov/agent/agentlist-category.asp

8.    Maurin M, Gyuranecz M. Tularaemia: clinical aspects in Europe. Lancet Infect Dis 2016; 16:113-124. PMID: 26738841.

9.    Appelt S, Faber M, Köppen K, Jacob D, Grunow R, Heuner K. Francisella tularensis subspecies holarctica and tularemia in Germany. Microorganisms 2020; 8:1448. PMID: 32971773. PMCID: PMC7564102.

10.    Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2018. ISBN: 978-3-89606-297-0.

11.    Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2019. ISBN: 978-3-89606-306-9.

12.    Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2020. ISBN 978-3-89606-311-3.

13.    Petersen JM, Schriefer ME, Gage KL, Montenieri JA, Carter LG, Stanley M, Chu MC. Methods for enhanced culture recovery of Francisella tularensis. Appl Environ Microbiol 2004; 70: 3733-3735. PMID: 15184180. PMCID: PMC427758.

14.    Humrighouse BW, Adcock NJ, Rice EW. Use of acid treatment and a selective medium to enhance the recovery of Francisella tularensis from water. Appl Environ Microbiol 2011; 77: 6729-6732. PMID: 21803910. PMCID: PMC3187174.

15.    Porsch-Ozcürümez M, Kischel N, Priebe H, Splettstösser W, Finke EJ, Grunow R. Comparison of enzyme-linked immunosorbent assay, Western blotting, microagglutination, indirect immunofluorescence assay, and flow cytometry for serological diagnosis of tularemia. Clin Diagn Lab Immunol 2004; 11: 1008-1015. PMID: 15539498. PMCID: PMC524736.

16.    Splettstoesser WD, Piechotowski I, Buckendahl A, Frangoulidis D, Kaysser P, Kratzer W, Kimmig P, Seibold E, Brockmann SO. Tularemia in Germany: the tip of the iceberg? Epidemiol Infect 2009; 137:736-743. PMID: 18808726.

17.    Jenzora A, Jansen A, Ranisch H, Lierz M, Wichmann O, Grunow R. Seroprevalence study of Francisella tularensis among hunters in Germany. FEMS Immunol Med Microbiol 2008; 53:183-189. PMID: 18462387.

18.    Borgschulte HS, Jacob D, Zeeh J, Scholz HC, Heuner K. Ulceroglandular form of tularemia after squirrel bite: a case report. J Med Case Rep 2022; 16:309. PMID: 35974355. PMCID: PMC9381146.

19.    Böhm S, Vom Berge K, Hierhammer D, Jacob D, Grunow R, Riehm JM, Konrad R, Dauer M, Bouschery B, Hossain H, Schichtl E, Böhmer MM. Epidemiological investigation of a tularaemia outbreak after a hare hunt in Bavaria, Germany, 2018. Zoonoses Public Health 2022; 69:106-116. PMID: 34780120.

20.    Whitehouse CA, Kesterson KE, Duncan DD, Eshoo MW, Wolcott M. Identification and characterization of Francisella species from natural warm springs in Utah, USA. Lett Appl Microbiol 2012; 54:313-324. PMID: 22283482.

21.    Guerpillon B, Boibieux A, Guenne C, Ploton C, Ferry T, Maurin M, Forestier E, Dauwalder O, Manipoud P, Ltaïef-Boudrigua A, Gürkov R, Vandenesch F, Bouchiat C. Keep an ear out for Francisella tularensis: otomastoiditis cases after canyoneering. Front Med (Lausanne) 2016; 3:9. PMID: 26973838. PMCID: PMC4776157.

22.    Kwit NA, Schwartz A, Kugeler KJ, Mead PS, Nelson CA. Human tularaemia associated with exposure to domestic dogs-United States, 2006-2016. Zoonoses Public Health 2019; 66:417-421. PMID: 30556330. PMCID: PMC7122577.

23.    Kittl S, Francey T, Brodard I, Origgi FC, Borel S, Ryser-Degiorgis MP, Schweighauser A, Jores J. First European report of Francisella tularensis subsp. holarctica isolation from a domestic cat. Vet Res 2020; 51:109. PMID: 32867856. PMCID: PMC7457513.

24.    Mínguez-González O, Gutiérrez-Martín CB, Martínez-Nistal MDC, Esquivel-García MDR, Gómez-Campillo JI, Collazos-Martínez JÁ, Fernández-Calle LM, Ruiz-Sopeña C, Tamames-Gómez S, Martínez-Martínez S, Caminero-Saldaña C, Hernández M, Rodríguez-Lázaro D, Rodríguez-Ferri EF. Tularemia outbreaks in Spain from 2007 to 2020 in humans and domestic and wild animals. Pathogens 2021; 10:892. PMID: 34358042. PMCID: PMC8308475.

25.    Djordjevic-Spasic M, Potkonjak A, Kostic V, Lako B, Spasic Z. Oropharyngeal tularemia in father and son after consumption of under-cooked rabbit meat. Scand J Infect Dis 2011; 43:977-981. PMID: 21736510.

26.    Burckhardt F, Hoffmann D, Jahn K, Heuner K, Jacob D, Vogt M, Bent S, Grunow R, Zanger P. Oropharyngeal tularemia from freshly pressed grape must. N Engl J Med 2018; 379:197-199. PMID: 29996079.

Maribavir – eine neue Therapieoption bei refraktärer Zytomegalievirus (CMV)-Infektion (Seite 39)

1. Halpern-Cohen V, Blumberg EA. New Perspectives on Antimicrobial Agents: Maribavir. Antimicrob Agents Chemother 2022; 66(9):e0240521; published online Aug 2, 2022. doi: 10.1128/aac.02405-21
 

2. European Medicines Agency (EMA). Livtencity (Maribavir): European public assessment report EMEA/H/C/005787/0000. Sep 15, 2022. Report

3. European Medicines Agency (EMA). Livtencity (Maribavir): Summary of Product Characteristics. Mar 17, 2022.

Product Information

4. Prichard, MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009;19(4):215-229. doi: 10.1002/rmv.615
 

5. Avery, RK. et al. Maribavir for refractory cytomegalovirus infections with or
without resistance posttransplant: results from a phase 3 randomized clinical trial. Clin Infect Dis 2022; 75(4):690-701. doi: 10.1093/cid/ciab988
 

6. Marty, FM. et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11(4):284-292.

doi: 10.1016/S1473-3099(11)70024-X